KR20040030609A - 경상이성체성 순수 에스시탈로프람의 용도 - Google Patents

경상이성체성 순수 에스시탈로프람의 용도 Download PDF

Info

Publication number
KR20040030609A
KR20040030609A KR10-2003-7014286A KR20037014286A KR20040030609A KR 20040030609 A KR20040030609 A KR 20040030609A KR 20037014286 A KR20037014286 A KR 20037014286A KR 20040030609 A KR20040030609 A KR 20040030609A
Authority
KR
South Korea
Prior art keywords
escitalopram
treatment
pharmaceutical composition
disorders
citalopram
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR10-2003-7014286A
Other languages
English (en)
Korean (ko)
Inventor
산케스코니
링옌센예스페르
뫼르크아르네
Original Assignee
하. 룬트벡 아크티에 셀스카브
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 하. 룬트벡 아크티에 셀스카브 filed Critical 하. 룬트벡 아크티에 셀스카브
Publication of KR20040030609A publication Critical patent/KR20040030609A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
KR10-2003-7014286A 2001-05-01 2002-05-01 경상이성체성 순수 에스시탈로프람의 용도 Ceased KR20040030609A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200100684 2001-05-01
DKPA200100684 2001-05-01
PCT/DK2002/000281 WO2002087566A1 (en) 2001-05-01 2002-05-01 The use of enantiomeric pure escitalopram

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020097027003A Division KR20100012089A (ko) 2001-05-01 2002-05-01 경상이성체성 순수 에스시탈로프람의 용도

Publications (1)

Publication Number Publication Date
KR20040030609A true KR20040030609A (ko) 2004-04-09

Family

ID=8160464

Family Applications (2)

Application Number Title Priority Date Filing Date
KR10-2003-7014286A Ceased KR20040030609A (ko) 2001-05-01 2002-05-01 경상이성체성 순수 에스시탈로프람의 용도
KR1020097027003A Ceased KR20100012089A (ko) 2001-05-01 2002-05-01 경상이성체성 순수 에스시탈로프람의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020097027003A Ceased KR20100012089A (ko) 2001-05-01 2002-05-01 경상이성체성 순수 에스시탈로프람의 용도

Country Status (25)

Country Link
US (7) US20040198809A1 (https=)
EP (1) EP1385503A1 (https=)
JP (1) JP2004527551A (https=)
KR (2) KR20040030609A (https=)
CN (1) CN1509169A (https=)
AR (1) AR033308A1 (https=)
AT (1) AT10974U1 (https=)
BG (1) BG108379A (https=)
BR (1) BR0208283A (https=)
CA (1) CA2445843A1 (https=)
CZ (1) CZ20033267A3 (https=)
EA (1) EA200301195A1 (https=)
HR (1) HRP20030744A2 (https=)
HU (1) HUP0400054A3 (https=)
IL (1) IL158031A0 (https=)
IS (1) IS6954A (https=)
ME (1) MEP5908A (https=)
MX (1) MXPA03008777A (https=)
NO (1) NO20034538D0 (https=)
PL (1) PL367480A1 (https=)
SK (1) SK14612003A3 (https=)
UA (1) UA82828C2 (https=)
WO (1) WO2002087566A1 (https=)
YU (1) YU85303A (https=)
ZA (1) ZA200307102B (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
EA200301195A1 (ru) * 2001-05-01 2004-04-29 Х. Лундбекк А/С Применение энантиомерно чистого эсциталопрама
UA80170C2 (en) * 2002-12-23 2007-08-27 Lundbeck & Co As H Escitalopram hydrobromide
US20050037983A1 (en) * 2003-03-11 2005-02-17 Timothy Dinan Compositions and methods for the treatment of depression and other affective disorders
AR047553A1 (es) * 2003-07-04 2006-01-25 Lundbeck & Co As H La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina
US20050176680A1 (en) * 2003-12-11 2005-08-11 Sepracor, Inc. Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
AU2005218713B2 (en) * 2004-03-05 2009-11-19 H. Lundbeck A/S Crystalline composition containing escitalopram oxalate
US20050196453A1 (en) 2004-03-05 2005-09-08 H. Lundbeck A/S Crystalline composition containing escitalopram
TWI358407B (en) * 2005-06-22 2012-02-21 Lundbeck & Co As H Crystalline base of escitalopram and orodispersibl
EP1954257A4 (en) * 2005-10-14 2009-05-20 Lundbeck & Co As H METHOD FOR TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM WITH A LOW-DOSED COMBINATION OF ESCITALOPRAM AND BUPROPION
AU2006304889A1 (en) * 2005-10-14 2007-04-26 H. Lundbeck A/S Stable pharmaceutical formulations containing escitalopram and bupropion
US20070134322A1 (en) * 2005-12-14 2007-06-14 Forest Laboratories, Inc. Modified and pulsatile release pharmaceutical formulations of escitalopram
CN100353939C (zh) * 2006-01-05 2007-12-12 昆明积大制药有限公司 含西酞普兰和环糊精的抗抑郁口服药用组合物
TW200812993A (en) * 2006-05-02 2008-03-16 Lundbeck & Co As H New uses of escitalopram
US20070259952A1 (en) * 2006-05-02 2007-11-08 H. Lundbeck A/S Uses of escitalopram
CA2672925A1 (en) * 2006-10-20 2008-04-24 Ratiopharm Gmbh Escitalopram and solid pharmaceutical composition comprising the same
JP5404048B2 (ja) * 2006-10-27 2014-01-29 久光製薬株式会社 貼付剤
EP2017271A1 (en) 2007-07-06 2009-01-21 Aurobindo Pharma Limited Process for the preparation of escitalopram
CN101815519B (zh) * 2007-08-03 2013-08-21 吉瑞工厂 包含多巴胺受体配体的药物组合物和使用多巴胺受体配体的治疗方法
EP2248808B1 (en) * 2008-01-31 2014-07-16 Takeda Pharmaceutical Company Limited Prophylactic or therapeutic agent for attention deficit/hyperactivity disorder
ITMI20080768A1 (it) * 2008-04-24 2009-10-25 Abiogen Pharma Spa Procedimento per la preparazione di un composto in forma cristallina di 3-benzil-2-metil-2,3,3a,4,5,6,7,7a-ottaidro-benzo[d]isossazol-4-one
WO2010098230A1 (ja) * 2009-02-27 2010-09-02 久光製薬株式会社 経皮投与製剤
US20180071269A1 (en) 2015-08-12 2018-03-15 Tianxin Wang Therapeutical methods, formulations and nutraceutical formulations
EP3294337B1 (en) * 2015-05-13 2024-12-18 Arvid Carlsson Research AB Treatment of debilitating fatigue by combined use of 3(s)-3-[3-(methylsulfonyl)phenyl]-1- propylpiperidine and an anti-depressive agent

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1143702A (https=) * 1965-03-18
US4079135A (en) * 1973-12-13 1978-03-14 Imperial Chemical Industries Limited Morpholine derivatives as antidepressants
GB1526331A (en) * 1976-01-14 1978-09-27 Kefalas As Phthalanes
GB8419963D0 (en) * 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method
GB8607313D0 (en) * 1986-03-25 1986-04-30 Ici Plc Pharmaceutical compositions
GB8814057D0 (en) * 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
US4902710A (en) * 1988-12-14 1990-02-20 Eli Lilly And Company Serotonin and norepinephrine uptake inhibitors
US5114976A (en) * 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US4962128A (en) * 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
US5296507A (en) * 1990-09-06 1994-03-22 H.Lundbeck A/S Treatment of cerbrovascular disorders
US5708035A (en) * 1991-02-04 1998-01-13 Sepracor Inc. Methods of use and compositions of R(-) fluoxetine
EP0714663A3 (en) * 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
US5627196A (en) * 1995-01-17 1997-05-06 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5554383A (en) * 1995-04-06 1996-09-10 Trustees Of Tufts College Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression
SE9501567D0 (sv) * 1995-04-27 1995-04-27 Astra Ab A new combination
US5846982A (en) * 1996-06-14 1998-12-08 Eli Lilly And Company Inhibition of serotonin reuptake
US5747494A (en) * 1996-06-28 1998-05-05 U C B S.A. Pharmaceutical compositions for the treatment of depressive disorders
US5958429A (en) * 1996-08-16 1999-09-28 Eli Lilly And Company Potentiation of serotonin response
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
US5776969A (en) * 1997-02-27 1998-07-07 Eli Lilly And Company Treatment of sleep disorders
US6069177A (en) * 1997-07-08 2000-05-30 The Hong Kong University Of Science And Technology 3-Hydroxy-propanamine derived neuronal reuptake inhibitors
SE9703375D0 (sv) * 1997-09-18 1997-09-18 Astra Ab A new combination
EP1042310B1 (en) * 1997-11-11 2002-07-31 H. Lundbeck A/S Method for the preparation of citalopram
EP1100501A4 (en) * 1998-06-30 2002-12-04 Lilly Co Eli PYRROLIDINE AND PYRROLIDINE DERIVATIVES INFLUENTING THE SYSTEMS ASSOCIATED WITH SEROTONIN
US6150376A (en) * 1998-08-05 2000-11-21 Georgetown University Bi- and tri-cyclic aza compounds and their uses
CA2291134C (en) * 1998-10-20 2006-05-23 H. Lundbeck A/S Method for the preparation of citalopram
AU759716B2 (en) * 1999-04-14 2003-04-17 H. Lundbeck A/S Method for the preparation of citalopram
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
US6333357B1 (en) * 1999-11-05 2001-12-25 Be Able, Llc Behavior chemotherapy
UA77650C2 (en) * 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
GB2357762B (en) * 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
WO2001080845A2 (en) * 2000-04-24 2001-11-01 Aryx Therapeutics (2-aminoethyl) oxime derivatives for the treatment of depression
EA200301195A1 (ru) * 2001-05-01 2004-04-29 Х. Лундбекк А/С Применение энантиомерно чистого эсциталопрама

Also Published As

Publication number Publication date
CA2445843A1 (en) 2002-11-07
US20080004338A1 (en) 2008-01-03
ZA200307102B (en) 2004-09-13
YU85303A (sh) 2006-05-25
KR20100012089A (ko) 2010-02-05
US20040198810A1 (en) 2004-10-07
IL158031A0 (en) 2004-03-28
IS6954A (is) 2003-09-15
NO20034538L (no) 2003-10-09
US20040192764A1 (en) 2004-09-30
HRP20030744A2 (en) 2005-06-30
BR0208283A (pt) 2004-03-09
US20040198811A1 (en) 2004-10-07
EP1385503A1 (en) 2004-02-04
US20040192765A1 (en) 2004-09-30
PL367480A1 (en) 2005-02-21
MEP5908A (xx) 2010-02-10
CN1509169A (zh) 2004-06-30
HUP0400054A2 (hu) 2004-04-28
US20040198809A1 (en) 2004-10-07
WO2002087566A1 (en) 2002-11-07
MXPA03008777A (es) 2004-02-12
NO20034538D0 (no) 2003-10-09
UA82828C2 (en) 2008-05-26
BG108379A (bg) 2004-11-30
SK14612003A3 (sk) 2004-04-06
CZ20033267A3 (en) 2004-06-16
EA200301195A1 (ru) 2004-04-29
AT10974U1 (de) 2010-02-15
AR033308A1 (es) 2003-12-10
US20040192766A1 (en) 2004-09-30
JP2004527551A (ja) 2004-09-09
HUP0400054A3 (en) 2007-03-28

Similar Documents

Publication Publication Date Title
KR20040030609A (ko) 경상이성체성 순수 에스시탈로프람의 용도
HU225534B1 (en) Pharmaceutical compositions comprising mirtazapine and one or more selective serotonin reuptake inhibitors
MXPA04011762A (es) Una combinacion de antagonista de nmda e inhibidores de acetilcolinesterasa para el tratamiento de la enfermedad de alzheimer.
AU2007253684A1 (en) Treatment for depressive disorders
US6387956B1 (en) Methods of treating obsessive-compulsive spectrum disorders
JP2024041855A (ja) 大うつ病性障害の処置方法
JPS59193821A (ja) 抗不安薬としてのフルオキセチンの使用法
Palaniyappan et al. Combining antidepressants: a review of evidence
CA2373757A1 (en) Treatment of neurotic disorders
Ng et al. Venlafaxine and bilateral acute angle closure glaucoma
Bystritsky et al. Pilot open‐label study of nefazodone in panic disorder
WO2008035177A2 (en) Combination of mt1 and mt2 melatonin receptor agonists and a norepinephrine/dopamine reuptake inhibitor
AU2002254870A1 (en) The use of enantiomeric pure escitalopram
AU2008201217A1 (en) The use of enantiomeric pure escitalopram
HK1067047A (en) The use of enantiomeric pure escitalopram
HRP20100463A2 (hr) Upotreba čistog enantiomernog citaloprama
KR20010099648A (ko) 신규 조성물
US20250241933A1 (en) Methods of treating sleep apnea with a combination of a cannabinoid and a carbonic anhydrase inhibitor
AU2004313648B2 (en) Combinations of serotonin reuptake inhibitors and imidazoline-I2-agonists
CN107952075A (zh) 一种含大麻二酚的组合物及其应用
AU2012307535A1 (en) Combinations comprising a S1P receptor modulator
Alberti et al. Gabapentin and valproate as an adjunct in the neuroleptic treatment of manic syndromes
Wade et al. Escitalopram 10 mg/day is an effective and well-tolerated first-line antidepressant in primary care
Dodd et al. Duloxetine for major depression
AU6377999A (en) A new composition

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20031101

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20040616

Comment text: Request for Examination of Application

AMND Amendment
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20051214

Patent event code: PE09021S01D

AMND Amendment
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20081114

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20090825

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20081114

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20051214

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20091125

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20090825

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20110729

Appeal identifier: 2009101010723

Request date: 20091125

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20091224

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20091125

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20091125

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20090413

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20080714

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20040722

Patent event code: PB09011R02I

B601 Maintenance of original decision after re-examination before a trial
PB0601 Maintenance of original decision after re-examination before a trial
J301 Trial decision

Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20091125

Effective date: 20110729

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20110729

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20091125

Decision date: 20110729

Appeal identifier: 2009101010723